Octreotide LAR (Sandostatin LAR)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Long-acting dosage form of Octreotide (Sandostatin). The LAR depot formulation consists of octreotide contained within biodegradable glucose star polymer microspheres; octreotide is gradually released as the polymer degrades via hydrolysis. Octreotide (Sandostatin) is a long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: IM
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

History of changes in PMDA indication

  • 2011-11-25: New additional indication and a new dosage for the treatment of gastrointestinal neuroendocrine tumor.

Patient drug information

Also known as

  • Generic names: octreotide acetate for injectable suspension, octreotide long-acting release
  • Brand names: Longastatina LAR, Sandostatin LAR, Sandostatin LAR Depot, Sandostatina LAR, Sandostatine LAR